title: Cardiopulmonary hemodynamics in systemic sclerosis and response to nifedipine and captopril.
abstract: OBJECTIVE
  This prospective study was performed to evaluate the response of the cardiopulmonary vasculature to two vasodilators in patients with systemic sclerosis and either minimal or no central hemodynamic abnormalities.
  
  
  METHODS
  Twenty patients with systemic sclerosis, Raynaud's phenomenon (19 of 20 patients), and clinically normal cardiac function underwent right heart catheterization. Rest and exercise hemodynamic measurements, including cardiac output by thermodilution, were performed before and after oral administration of nifedipine 20 mg and captopril 25 mg.
  
  
  RESULTS
  Half of the patients had normal hemodynamics (Group A); the other half (Group B) had abnormal baseline elevations in pulmonary vascular resistance and four of them showed "borderline" pulmonary arterial hypertension. Group A, with significantly shorter disease duration compared with Group B, responded poorly to nifedipine and captopril. However, Group B had significant decreases in pulmonary vascular resistance (from 148 +/- 20 to normal levels of 94 +/- 21 dynes.second.cm-5) and pulmonary mean pressure in response to nifedipine treatment but not to captopril.
  
  
  CONCLUSIONS
  These observations show a short-term beneficial effect of nifedipine in the cardiopulmonary vasculature of patients with systemic sclerosis and suggest that a potentially reversible vasoconstrictive element is included in the vascular lesion of this disorder.
authors.affiliation: Cardiac Department, Hippokration Hospital, Athens, Greece.
authors.forename: P P
authors.initials: PP
authors.lastname: Sfikakis
authors.forename: M K
authors.initials: MK
authors.lastname: Kyriakidis
authors.forename: C G
authors.initials: CG
authors.lastname: Vergos
authors.forename: G P
authors.initials: GP
authors.lastname: Vyssoulis
authors.forename: T K
authors.initials: TK
authors.lastname: Psarros
authors.forename: C A
authors.initials: CA
authors.lastname: Kyriakidis
authors.forename: M E
authors.initials: ME
authors.lastname: Mavrikakis
authors.forename: P P
authors.initials: PP
authors.lastname: Sfikakis
authors.forename: P K
authors.initials: PK
authors.lastname: Toutouzas
mesh_terms: D000284:Administration, Oral; D000328:Adult; D002216:Captopril / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use*; D006328:Cardiac Catheterization; D002318:Cardiovascular Diseases / Q000175:diagnosis / Q000188:drug therapy* / Q000503:physiopathology; D005080:Exercise Test; D005260:Female; D006439:Hemodynamics / Q000187:drug effects*; D006801:Humans; D008297:Male; D008875:Middle Aged; D009543:Nifedipine / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use*; D011446:Prospective Studies; D012595:Scleroderma, Systemic / Q000175:diagnosis / Q000188:drug therapy* / Q000503:physiopathology; D014655:Vascular Resistance / Q000187:drug effects
chemical_list: D002216:Captopril; D009543:Nifedipine